Basecamp Research has raised $140 million in a Series C round to expand its biological AI models and move an early therapeutic pipeline toward clinical development. For life-sciences technology teams, the financing provides another measure of how AI drug-development platforms are moving from research tooling toward the costly work of developing potential treatments.
The oversubscribed round was led by S32 and included a group of venture, institutional and strategic investors. Basecamp said it will use the capital to train a new generation of its EDEN biological foundation models, advance therapeutics designed with those models and expand pharmaceutical partnerships.
The company’s near-term focus is in vivo cell therapy, an approach intended to reprogram a patient’s cells inside the body. Basecamp said conventional cell therapies can be limited by the complexity of treatments they can deliver and by manufacturing processes that can cost hundreds of thousands of dollars per patient.
Basecamp is pairing its EDEN models’ ability to design long DNA sequences with large serine recombinases, enzymes intended to integrate those sequences into a genome. The company said the combination could support more sophisticated and customizable cell therapies that are simpler to administer. Its stated areas of interest include cancer and autoimmune disease.
The technology remains preclinical. Basecamp said it has demonstrated preclinical results across multiple modalities and disease areas, but it did not provide clinical trial results, regulatory milestones or timelines for a therapeutic candidate entering human testing.
The distinction matters for enterprise buyers and pharmaceutical partners evaluating AI-driven biology platforms. Generative AI can accelerate the identification and design of potential candidates, but it does not replace the validation, manufacturing, safety testing and regulatory work needed to establish whether a treatment can reach patients.
Basecamp’s platform rests on EDEN, a biological foundation model trained on the company’s Trillion Gene Atlas, a proprietary dataset built from biological data collected through access-and-benefit-sharing partnerships in more than 30 countries. The company describes the atlas as its largest proprietary biological AI training dataset.
According to the company, the models are designed to recognize patterns across diverse biological data rather than focus on one scientific task. Basecamp said that design allows EDEN to generate potential therapeutic candidates from disease-related information and to support work on cell and gene therapies, enzymes and peptides.
That broad-model approach could be commercially significant if it proves repeatable across multiple therapeutic programs. Pharmaceutical companies often use separate specialized tools and workflows for discovery, target validation, molecular design and preclinical development. A platform that can contribute across several stages could reduce handoffs between data, modeling and laboratory teams—though Basecamp has not established those operational gains with customer results.
The financing also signals continued investor interest in AI systems that combine proprietary scientific data with models tailored to a specific industry. General-purpose AI models can support scientific research, but life-sciences companies are also pursuing systems trained on biological data and connected to experimental validation.
Basecamp has appointed a chief business officer to expand pharmaceutical partnerships. That role will be central to whether the company’s platform progresses from a research asset to a practical development partner for drugmakers.
The competitive change is not simply more AI in drug discovery. It is the attempt to connect data collection, biological modeling and therapeutic design in a single platform. Legacy discovery workflows remain fragmented across software, laboratory operations and external research partners; Basecamp’s strategy will be tested by whether its preclinical work can translate into validated, clinically useful therapies.